Shuttle Pharmaceuticals Holdings, INC

Shuttle Pharmaceuticals Holdings, Inc. has implemented a 1-for-10 reverse stock split effective June 11, 2026, to adjust its common stock structure.

Shuttle Pharmaceuticals Holdings announced the results of its 2026 Annual Meeting of Stockholders, with key proposals including director elections, auditor ratification, executive compensation advisory vote, and a reverse stock split authorization receiving approval.

Shuttle Pharmaceuticals Holdings, Inc. has finalized its merger with United Dogecoin Inc. and secured $9.55 million in PIPE financing.

Shuttle Pharmaceuticals Holdings, Inc. announced a definitive merger with United Dogecoin Inc. and an $11 million PIPE financing, aiming to become the largest publicly listed Dogecoin miner.

Shuttle Pharmaceuticals Holdings, Inc. has extended the consulting agreement for interim co-Chief Executive Officer Christopher Cooper through August 1, 2026.

Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Yuying Liang as Chief Financial Officer and the resignation of Sachin Pathigoda from its Board of Directors.

Shuttle Pharmaceuticals Holdings, Inc. reported a significant net loss for Q3 2025, faced termination of its primary CRO agreement, and secured new equity financing while expressing substantial doubt about its ability to continue as a going concern.

Shuttle Pharmaceuticals Holdings, Inc. reported a significantly wider net loss in Q2 2025, raising $8.9 million in net proceeds from equity financings but still facing substantial doubt about its ability to continue as a going concern.

Shuttle Pharmaceuticals Holdings, Inc. announces its financial results for the first quarter of 2025, showcasing a recent $5 million equity financing and ongoing clinical trial developments.

Shuttle Pharmaceuticals reported a net loss of $7.5 million for the nine months ended September 30, 2024, and faces substantial doubt about its ability to continue as a going concern despite recent capital raises.

Shuttle Pharmaceuticals reported a net loss of $3.8 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern.

Shuttle Pharmaceuticals Holdings, Inc. has restated its financial statements for 2022 and 2023 due to accounting errors identified after its former auditor faced a cease-and-desist order from the SEC, and is now planning a capital raise to fund operations and clinical trials.

Shuttle Pharmaceuticals Holdings reports a net loss of $9.1 million for 2024 and acknowledges substantial doubt about its ability to continue as a going concern without additional financing.

Shuttle Pharmaceuticals Holdings, Inc. has amended its annual report to restate its financial statements for 2022 and 2023 due to accounting errors and material weaknesses in internal controls.

Shuttle Pharmaceuticals reports a net loss of $6.6 million for 2023, while advancing its lead drug candidate, Ropidoxuridine, to a Phase II clinical trial.

Hrt Financial Lp reported changes in beneficial ownership of Shuttle Pharmaceuticals Holdings, Inc. common stock on July 9, 2026.

Hrt Financial Lp reported changes in beneficial ownership of Shuttle Pharmaceuticals Holdings, Inc. common stock on July 9, 2026.

HRT FINANCIAL LP reports significant transactions in Shuttle Pharmaceuticals Holdings, Inc. common stock.

HRT FINANCIAL LP reports significant stock transactions in Shuttle Pharmaceuticals Holdings, Inc., indicating changes in beneficial ownership.

HRT Financial LP reports a significant acquisition of common stock in Shuttle Pharmaceuticals Holdings, Inc., increasing its beneficial ownership.

HRT Financial LP reports significant stock acquisitions in Shuttle Pharmaceuticals Holdings, Inc. on June 29th and June 30th, 2026.

Shuttle Pharmaceuticals Holdings, Inc. seeks shareholder approval for a reverse stock split of up to 1-for-150 to maintain Nasdaq listing compliance.

Shuttle Pharmaceuticals is seeking stockholder approval for two proposals to issue more than 20% of its common stock at a discount to market price, aiming to secure funding for its Phase 2 clinical trial of Ropidoxuridine.

Shuttle Pharmaceuticals is asking stockholders to approve a reverse stock split, an increase in shares reserved for its equity incentive plan, and the issuance of common stock upon conversion of convertible notes.

Shuttle Pharmaceuticals reports progress on its lead program, Ropidoxuridine, and seeks shareholder approval for a reverse stock split to maintain Nasdaq compliance.

Shuttle Pharmaceuticals is asking shareholders to approve a reverse stock split while advancing its lead drug candidate, Ropidoxuridine, into a Phase 2 clinical trial for glioblastoma.

Shuttle Pharmaceuticals Holdings, Inc. is offering up to 2,229,300 shares of common stock and pre-funded warrants to raise capital, signaling a strategic shift to AI-driven drug discovery following the acquisition of Molecule.ai and the discontinuance of its clinical trials.

Shuttle Pharmaceuticals Holdings, Inc. is registering shares for resale by a selling stockholder following a strategic pivot to AI-driven drug discovery and the discontinuance of its lead clinical program.

Shuttle Pharmaceuticals registered 625,156 shares for resale tied to a November 2025 pre‑funded warrant, adding a potential stock overhang while providing no proceeds to the company.

Shuttle Pharmaceuticals Holdings, Inc. filed an S-1 registration statement for the resale of 1,180,877 shares of common stock by a selling stockholder, stemming from a recent private placement.

Shuttle Pharmaceuticals is launching a public offering of up to 10 million shares of common stock, with pre-funded warrants available as an alternative for certain investors.

Shuttle Pharmaceuticals plans a firm commitment underwritten offering of common stock and pre-funded warrants to advance its cancer treatment pipeline.

Armistice Capital and Steven Boyd have reduced their beneficial ownership in Shuttle Pharmaceuticals Holdings, Inc. to 4.99% of common stock.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 9.99% in Shuttle Pharmaceuticals Holdings, Inc.'s common stock as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 7.51% in Shuttle Pharmaceuticals Holdings, Inc., totaling 306,057 shares of common stock as of December 31, 2024.